Search PubMed⌕ Search

Biomedical subjects

T Misaki

Publications and source records attributed to T Misaki.

At least 253 records · Page 14Linked to original sources
PubMed1986

Clinical evaluation of radiotherapy for Graves' ophthalmopathy.

Seventeen patients with moderately severe ophthalmopathy due to Graves' disease were treated by cobalt or supervoltage radiotherapy. All patients complained of diplopia. The mean proptosis value was 21.4 mm. Three patients (18%) showed good response, 7 (41%) moderate and 7 minimal or no response. Improvement was noted mainly in soft tissue changes and diplopia, while proptosis decreased in only 5 patients. All except one patient who had marked extraocular muscle involvement revealed by computed tomography responded to treatment. These data indicate that radiotherapy may be indicated in patients with progressive ophthalmopathy, especially in those who are associated with extraocular muscle enlargement.

Adult↗
PubMed1986

Paired determination of thyroid-stimulating and TSH-binding inhibitory activities in patients with Graves' disease during antithyroid drug treatment.

Sequential changes in thyroid-stimulating antibodies (TSAb) and TSH-binding inhibitor immunoglobulins (TBII) during antithyroid drug treatment were studied in 17 patients with Graves' disease. Before treatment, TSAb and TBII were detected in 17 (100%) and 13 (76.5%) patients, respectively, with a significant correlation between the two activities (r = 0.600, n = 17, P less than 0.02). In 9 patients who became euthyroid as early as after 1-4 months of treatment, the TSAb and TBII activities both gradually decreased, and there was a good correlation between the changes of these activities during treatment. Among the 7 patients in whom small changes in TSAb and TBII activities were observed, 4 showed poor control of the thyrotoxicosis during the whole observation period (7 months-2 years). One patient who showed a marked dissociation between the changes in TSAb and TBII activities developed hypothyroidism, when his TBII became remarkably high. These potent TBII inhibited cAMP production induced by bTSH. These findings indicate that 1) changes in TSAb and TBII activities reflect the clinical course of hyperthyroidism in most patients with Graves' disease, and 2) development of a blocking-type of TBII may induce hypothyroidism in some patients after the treatment.

Adolescent↗
PubMed1986

Length-based Fourier analysis in the pre-excitation syndrome.

Length-based Fourier analysis (LFA) was applied to tomographic gated blood-pool study, and phase and percent-shortening diagrams were generated. In 22 patients with pre-excitation syndrome and ten control subjects, the most basal short-axis section was used for tomographic analysis. When the initial abnormal phase was considered as the location of accessory conduction pathway (ACP), correct diagnosis for the localization of ACP was given in 19 of 22 patients. In ten control subjects, no specific segments of initial phase were noted, although six patients had initial phase in the septal or paraseptal segments. The tomographic LFA was more effective for pinpointing the segment of the earliest phase than tomographic count-based phase analysis. The LFA provided objective three-dimensional information for contraction sequence. Because movements of ventricular edges are essential in tomography, the LFA was considered to be a reasonable approach for the analysis of tomographic gated blood-pool study.

Erythrocytes↗
PubMed1986

[Photodynamic therapy of superficial bladder tumors].

Photodynamic therapy (PDT), using hematoporphyrin derivative (HPD) and the red light (wavelength 630 nm) of an argon-dye laser as the source of excitation energy was performed on 46 patients with superficial bladder tumors. Two methods of laser irradiation, (1) focal PDT using a 400 micron quartz fiber through a cystourethroscope in 22 patients with superficial bladder tumors and (2) whole bladder wall total PDT using a motor-driven laser light scattering device in 24 patients with multifocal carcinoma in situ and/or dysplasia of bladder mucosa associated with multicentric concurrent superficial tumors, were used. The patients in (2) had been referred for total cystectomy, and 19 of these 24 patients had a history of several transurethral resections, hyperthermia and/or instillation therapy. HPD 2-4 mg/kg was i.v. injected 48 to 72 hours before PDT. Judging from the results of 60 protrusions treated by focal PDT, the light power should be 200 mW/cm2 for 5-10 minutes or more and the total light energy should be 100 J/cm2 or more in tumors up to 2 cm in size. With focal PDT, 4 of the 22 patients had no recurrence with the mean tumor free time of 20.8 months. In 6 of the 24 patients treated with total PDT using 10, 20 or 30 J/cm2 of light energy, there was no recurrence with a mean tumor-free time of 7.5 months and there was no significant relationship between the recurrence rate and total light energy used.

Adult↗
PubMed1986

Radical surgical cure of Wolff-Parkinson-White syndrome: the Kanazawa experience.

Between 1973 and 1983, we operated on 160 patients with Wolff-Parkinson-White syndrome at Kanazawa University Hospital; 126 had Wolff-Parkinson-White syndrome alone, and 34 had combined cardiac diseases. Of the 160 patients, 140 were completely cured; postoperatively, they had no delta wave on electrocardiograms and no tachycardia attacks. In 11 patients, the delta wave reappeared an average of 56 days after operation. They, and three other patients with concealed Wolff-Parkinson-White syndrome, experienced several postoperative episodes of tachycardia. However, in 12 of the 14 patients with postoperative tachycardia attacks, these disappeared completely in the course of a long follow-up period and these patients are also considered to be cured symptomatically. In the two remaining patients, the tachycardia attacks persisted. Of the 126 patients with Wolff-Parkinson-White syndrome alone, none died as a direct result of the operation. Patients with combined cardiac diseases other than cardiomyopathy, mild Ebstein's anomaly, or venous abnormality were treated in one operation. Six of the 34 patients with combined cardiac diseases died. In none of the 160 patients was the His bundle intentionally interrupted as an alternative method of interrupting the accessory conduction pathway. Our study showed that life-threatening arrhythmias occur more often than expected in patients with Wolff-Parkinson-White syndrome and the tolerance for tachycardia attacks differs from patient to patient. Because the surgical treatment of Wolff-Parkinson-White syndrome is safe and reliable, as indicated in this report, the radical correction of this disease should be considered in carefully evaluated patients.

Adolescent↗
PubMed1985

Nuclear tomographic phase analysis: localization of accessory conduction pathway in patients with Wolff-Parkinson-White syndrome.

The purpose of this study was to evaluate the usefulness of tomographic phase analysis in detecting the site of the accessory conduction pathway (ACP) in patients with Wolff-Parkinson-White (WPW) syndrome. Gated emission computed tomography and planar gated blood pool scintigraphy were performed in 20 patients with WPW syndrome, 14 with delta waves and six without delta waves (two intermittent types and four concealed types). The abnormal initial contractions in both planar and tomographic phase images were compared with the sites of ACPs confirmed by epicardial mapping and surgery. The atrioventricular ring was divided into eight segments on each side, and the identification of the initial phase in the segment in which the ACP was located, or that adjacent to it, was considered to be the correct diagnosis. In planar phase analysis, the abnormal initial phase was identified correctly in 8 of 14 patients (57%), whereas in tomographic phase analysis, the site of the ACP was detected in 12 of 14 patients (86%). Tomographic phase analysis can be a helpful adjunctive method in patients with WPW syndrome.

Adolescent↗
PubMed1985

Primary myxedema with thyrotrophin-binding inhibitor immunoglobulins. Clinical and laboratory findings in 15 patients.

In a screening of 43 patients with primary myxedema, 9 patients were found to have IgG that inhibits the binding of 125I-thyrotrophin to its receptor (thyrotrophin-binding inhibitor immunoglobulins). Preparations of IgG from these patients did not stimulate thyroidal cyclic adenosine monophosphate generation and blocked thyroid stimulation by thyrotrophin in vitro. Clinical and laboratory features of 15 patients with this inhibitor, including 6 who were previously known, were compared with those of patients without the inhibitor. The patients with inhibitor, 2 men and 13 women, had onset of their hypothyroidism from age 2 to 49 years, and thyroid uptake in these patients was significantly lower than that in patients without inhibitor. Transient hypothyroidism was seen in all 5 infants born to 4 mothers having potent inhibitor immunoglobulins. These clinical findings indicate that thyrotrophin-receptor-blocking antibodies play a pathogenic role in a group of patients with primary myxedema.

Adolescent↗
PubMed1985

[Hyperthermic perfusion therapy using peplomycin for bladder cancer].

Hyperthermic intravesical perfusion therapy using peplomycin (40 micrograms/ml) in distilled water at 43 degrees C as a perfusate was performed for 2 to 3 hours in 18 patients with superficial bladder tumors and 2 with deep bladder tumors. The therapeutic efficacy was determined by cystoscopy, ultrasonography and/or CT scan. Complete and partial tumor regression was obtained in 1 and 3 of the 18 patients, respectively. There was no tumor regression in the 12 patients. Most of the patients studied had bladder discomfort such as irritation, urinary frequency and so on, during and/or after perfusion. None of the patients developed acute pyelonephritis.

Aged↗